Anti-Human IL-12 / IL-23 (Briakinumab Biosimilar)
英诺赛图(InnoCyto)的 Anti-Human IL-12 / IL-23 (Briakinumab Biosimilar)(克隆 Briakinumab) 为人源 IgG1 抗体,靶向 IL-12/IL-23。提供 1 mg、5 mg、20 mg 规格,目录价 ¥1,695 起,仅供科研使用(RUO)。
01产品图片

02产品简介
英诺赛图(InnoCyto)的 Anti-Human IL-12 / IL-23 (Briakinumab Biosimilar)(克隆 Briakinumab) 为人源 IgG1 抗体,靶向 IL-12/IL-23。提供 1 mg、5 mg、20 mg 规格,目录价 ¥1,695 起,仅供科研使用(RUO)。
03产品介绍
规格与货号
501001 | 1 mg | ¥1,695
501002 | 5 mg | ¥5,085
501003 | 20 mg | ¥13,560
Product Details
Application|Neutralization, Intracellular Flow cytometry, animal model study
Product Description|Anti-Human IL-12 / IL-23 (Briakinumab Biosimilar)
Regulatory Status|RUO
Species specificity|Human
Min Sample Size|1 mg
Storage Conditions|4ºC
Maximal Shelf Life|12 months
See All Formats|Clone Briakinumab
Background Information
Briakinumab is a recombinant, fully human monoclonal antibody that belongs to the immunoglobulin G1 (IgG1) subclass. It is designed to specifically bind to the shared p40 subunit of the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23), thereby interfering with their interaction with the interleukin-12 receptor β1 (IL-12Rβ1) on the surface of immune cells. Structurally, Briakinumab is a typical IgG1 molecule composed of two identical heavy chains and two identical light chains connected by disulfide bonds, forming a Y-shaped configuration. It has an approximate molecular weight of 148 kilodaltons (kDa) and is produced using mammalian expression systems, such as Chinese Hamster Ovary (CHO) cells, to ensure proper glycosylation and protein folding consistent with human antibodies.
The variable regions of the heavy and light chains in Briakinumab contain complementarity-determining regions (CDRs), which define its antigen-binding specificity. These regions form a paratope that engages with the p40 subunit of IL-12 and IL-23 through non-covalent interactions, including hydrogen bonding and van der Waals forces. By binding to the p40 subunit, Briakinumab prevents IL-12 and IL-23 from interacting with their receptor complexes on T cells and natural killer (NK) cells. This inhibition disrupts downstream signaling through the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, limiting the production of proinflammatory cytokines such as interferon-gamma (IFN-γ) and interleukin-17 (IL-17) in experimental systems.
The Fc region of Briakinumab provides structural stability, prolongs its serum half-life by interacting with neonatal Fc receptors (FcRn), and maintains effector functions characteristic of IgG1 antibodies. It is glycosylated at the asparagine 297 residue within the CH2 domain, contributing to molecular solubility and conformation.
Data Sheets
Cat # Size Price Quantity 5010011 mg Add to Cart5010025 mg Add to Cart50100320 mg Add to Cart
04完整参数表
参数由厂商资料整理,采购前请以最终报价单与技术协议为准。
05荣誉与资质
该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。
- 营业执照未上传
- 品牌授权未上传
- 产品检测报告未上传
- 会员身份
- 收费会员
- 经营身份
- 原厂
- 成立年份
- 2020 年
- 所在地
- 上海
- 收录条目
- 1865 个
- 平台核验
- 平台代管
06品牌与供应商
InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。
品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。
07同类条目
同一子类内的条目才具备可比性。跨子类比较参数通常没有意义。
08同品牌其他条目
上海英诺赛图 在本目录共 1865 个条目,除本条外还有:
科研在线(TeleVM). Anti-Human IL-12 / IL-23 (Briakinumab Biosimilar)(501001)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/anti-human-il-12-il-23-briakinumab-biosimilar.html.
TeleVM. (2026, November 12). Anti-Human IL-12 / IL-23 (Briakinumab Biosimilar)(501001). 产品目录. https://www.suprotek.cn/products/item/anti-human-il-12-il-23-briakinumab-biosimilar.html
@misc{biocsp_item_anti_human_il_12_il_23_briakinumab_biosimilar,
title = {Anti-Human IL-12 / IL-23 (Briakinumab Biosimilar)(501001)},
author = {{科研在线}},
year = {2026},
howpublished = {产品目录},
note = {更新于 2026-11-12,产品目录},
url = {https://www.suprotek.cn/products/item/anti-human-il-12-il-23-briakinumab-biosimilar.html}
}
GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。
许可:CC BY-NC 4.0 · 转载注明来源